Table 3.
C-index analysis of the prognostic accuracy of UBR5, CD163 and other variables for overall survival and progression-free survival in the training and validation cohorts (3:2 ratio)
| C-index (95% CI) | Overall survival | Progression-free survival | ||
|---|---|---|---|---|
| Training cohort (n = 186) | Validation cohort (n = 124) | Training cohort (n = 186) | Validation cohort (n = 124) | |
| TNM stage | 0.677 (0.634–0.72) | 0.684 (0.646–0.722) | 0.639 (0.61–0.669) | 0.647 (0.622–0.672) |
| SSIGN | 0.676 (0.644–0.709) | 0.679 (0.65–0.707) | 0.682 (0.663–0.701) | 0.63 (0.612–0.648) |
| UBR5 | 0.705 (0.643–0.768) | 0.757 (0.694–0.82) | 0.701 (0.656–0.745) | 0.727 (0.682–0.771) |
| CD163 | 0.683 (0.621–0.745) | 0.698 (0.633–0.764) | 0.675 (0.631–0.719) | 0.646 (0.6–0.693) |
| UBR5 + CD163 | 0.767 (0.697–0.837) | 0.803 (0.732–0.874) | 0.767 (0.717–0.816) | 0.749 (0.699–0.8) |
| UBR5 + CD163 + TNM stage | 0.804 (0.734–0.875) | 0.851 (0.779–0.923) | 0.801 (0.751–0.851) | 0.802 (0.751–0.853) |
| UBR5 + CD163 + SSIGN | 0.801 (0.73–0.871) | 0.852 (0.78–0.923) | 0.84 (0.79–0.89) | 0.791 (0.74–0.842) |